Skip to main content
SpringerLink
Log in

Role of Transforming Growth Factor-β in the Kidney — Physiology and Pathology

  • Chapter
Transforming Growth Factor-β in Cancer Therapy, Volume II

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1558 Accesses

Abstract

Chronic kidney diseases, characterized by a progressive course toward organ failure, represent an emerging world-wide public health problem. Common pathogenetic pathways of injury, irrespectively of the etiology, include glomerular capillary hypertension and enhanced passage of plasma proteins across the glomerular capillary barrier because of the impaired permselective function. These changes are associated with podocyte injury and glomerulosclerosis, consisting in the accumulation of the extracellular matrix material and obliteration of the capillary filter that contribute to the loss of renal function. Over the past several years, transforming growth factor-β (TGF-β) has been recognized as a central player in the pathogenesis of glomerulosclerosis owing to its activity of both stimulating matrix production and blocking matrix degradation.

This chapter discusses the role of TGF-β in progressive kidney diseases and describes the renoprotective potential of strategies that interfere with TGF-β production, as a new antifibrotic therapeutic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597–641.

    Article  PubMed  Google Scholar 

  2. Ando T, Okuda S, Tamaki K, Yoshitomi K, Fujishima M. Localization of transforming growth factorbeta and latent transforming growth factor-beta binding protein in rat kidney. Kidney Int 1995;47(3): 733–739.

    Article  CAS  PubMed  Google Scholar 

  3. MacKay K, Kondaiah P, Danielpour D, Austin HA, 3rd, Brown PD. Expression of transforming growth factor-beta 1 and beta 2 in rat glomeruli. Kidney Int 1990;38(6):1095–1100.

    Article  CAS  PubMed  Google Scholar 

  4. Wilson HM, Minto AW, Brown PA, Erwig LP, Rees AJ. Transforming growth factor-beta isoforms and glomerular injury in nephrotoxic nephritis. Kidney Int 2000;57(6):2434–2444.

    Article  CAS  PubMed  Google Scholar 

  5. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342(18):1350–1358.

    Article  CAS  PubMed  Google Scholar 

  6. Taipale J, Miyazono K, Heldin C-H, Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994;124(1–2): 171–181.

    Article  CAS  PubMed  Google Scholar 

  7. Miyazono K, Olofsson A, Colosetti P, Heldin C-H. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 1991;10(5):1091–1101.

    CAS  PubMed  Google Scholar 

  8. Nakajima Y, Miyazono K, Kato M, Takase M, Yamagishi T, Nakamura H. Extracellular fibrillar structure of latent TGF beta binding protein-1: role in TGF beta-dependent endothelial-mesenchymal transformation during endocardial cushion tissue formation in mouse embryonic heart. J Cell Biol 1997;136(1):193–204.

    Article  CAS  PubMed  Google Scholar 

  9. Mizoi T, Ohtani H, Miyazono K, Miyazawa M, Matsuno S, Nagura H. Immunoelectron microscopic localization of tranforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Cancer Res 1993;53(1):183–190.

    CAS  PubMed  Google Scholar 

  10. Eklov S, Funa K, Nordgren H, et al. Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue. Cancer Res 1993;53(13):3193–3197.

    CAS  PubMed  Google Scholar 

  11. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin C-H. Transforming growth factor-beta 1,_-beta 2, and_-beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992;267(27):19,482–19,488.

    CAS  PubMed  Google Scholar 

  12. Ando T, Okuda S, Yanagida T, Fujishima M. Localization of TGF-beta and its receptors in the kidney. Miner Electrolyte Metab 1998;24(2–3):149–153.

    Article  CAS  PubMed  Google Scholar 

  13. MacKay K, Striker LJ, Stauffer JW, Doi T, Agodoa LY, Striker GE. Transforming growth factor-beta. Murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest 1989;83(4): 1160–1167.

    Article  CAS  PubMed  Google Scholar 

  14. Shankland SJ, Pippin J, Pichler RH, et al. Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 1996;50(1):116–124.

    Article  CAS  PubMed  Google Scholar 

  15. Wang W, Huang XR, Li AG, et al. Signaling mechanism of TGF-β1 in prevention of renal inflammation: Role of Smad7. J Am Soc Nephrol 2005;16(5):1371–1383.

    Article  CAS  PubMed  Google Scholar 

  16. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307: 652–659.

    Article  CAS  PubMed  Google Scholar 

  17. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612–619.

    Article  CAS  PubMed  Google Scholar 

  18. Fries JW, Sandstrom DJ, Meyer TW, Rennke HG. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 1989;60(2):205–218.

    CAS  PubMed  Google Scholar 

  19. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384–394.

    Article  CAS  PubMed  Google Scholar 

  20. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339: 1448–1456.

    Article  CAS  PubMed  Google Scholar 

  21. Remuzzi G. Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens 1999;8:655–663.

    Article  CAS  PubMed  Google Scholar 

  22. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934–941.

    Article  CAS  PubMed  Google Scholar 

  23. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997;8:1537–1545.

    CAS  PubMed  Google Scholar 

  24. Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kB activation. Kidney Int 1998;53:1608–1615.

    Article  CAS  PubMed  Google Scholar 

  25. Yard BA, Chorianopoulos E, Herr D, van der Woude FJ. Regulation of endothelin-1 and transforming growth factor-betal production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant 2001;16:1769–1775.

    Article  CAS  PubMed  Google Scholar 

  26. Wolf G, Schroeder R, Ziyadeh FN, Stahl RA. Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. Kidney Int 2004;66(5):1849–1858.

    Article  CAS  PubMed  Google Scholar 

  27. Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int Suppl 1994;45:S58–S63.

    Article  CAS  PubMed  Google Scholar 

  28. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998;54(3):687–697.

    Article  CAS  PubMed  Google Scholar 

  29. Shih NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999;286(5438):312–315.

    Article  CAS  PubMed  Google Scholar 

  30. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein — nephrin—is mutated in congenital nephrotic syndrome. Mol Cell 1998;1(4):575–582.

    Article  CAS  PubMed  Google Scholar 

  31. Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet 2000;24(4):333–335.

    Article  CAS  PubMed  Google Scholar 

  32. Wickelgren I. First components found for new kidney filter. Science 1999;286(5438):225–226.

    Article  CAS  PubMed  Google Scholar 

  33. Border WA, Noble NA, Jamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361–364.

    Article  CAS  PubMed  Google Scholar 

  34. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix J Clin Invest 1990;86:453–462.

    CAS  Google Scholar 

  35. Abbate M, Zoja C, Morigi M, et al. Trasforming growth factor-betal is up-regulated by podocytes in response to excess intraglomerular passage of proteins. Am J Pathol 2002;161:2179–2193.

    CAS  PubMed  Google Scholar 

  36. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993;92:2597–2601.

    Article  CAS  PubMed  Google Scholar 

  37. Bruijn JA, Roos A, De Geus B, De Heer E. Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. J Lab Clin Med 1994;123:34–47.

    CAS  PubMed  Google Scholar 

  38. Roberts AB, Sporn M.B. The transforming growth factor-betas. In: Sporn MB, ed. Peptide Growth Factors and Their Receptors. Springer, Berlin, 1990:419–472.

    Google Scholar 

  39. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992;42(6):1462–1469.

    Article  CAS  PubMed  Google Scholar 

  40. Border WA, Noble WA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331: 1286–1292.

    Article  CAS  PubMed  Google Scholar 

  41. Bitzer M, Sterzel RB, Bottinger EP. Transforming growth factor-beta in renal disease. Kidney Blood Press Res 1998;21(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  42. Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000;58(6):2301–2313.

    Article  CAS  PubMed  Google Scholar 

  43. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000;58(6):2425–2436.

    Article  CAS  PubMed  Google Scholar 

  44. Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992;141(6):1381–1396.

    CAS  PubMed  Google Scholar 

  45. Nakamura T, Ebihara I, Fukui M, et al. Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin Immunol Immunopathol 1993;66(1):33–42.

    Article  CAS  PubMed  Google Scholar 

  46. Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, Fogo AB. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 2004;65(1): 106–115.

    Article  CAS  PubMed  Google Scholar 

  47. Abbate M, Zoja C, Rottoli D, Corna D, Tomasoni S, Remuzzi G. Proximal tubular cells promote fibrogenesis by TGF-β1-mediated induction of peritubular myofibroblasts. Kidney Int 2002;61: 2066–2077.

    Article  CAS  PubMed  Google Scholar 

  48. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta1 induces alphasmooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103–111.

    Article  PubMed  Google Scholar 

  49. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997;273:F563–F574.

    CAS  PubMed  Google Scholar 

  50. Zoja C, Corna D, Bruzzi I, et al. Passive Heymann Nephritis: Evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol 1996;4:213–221.

    CAS  PubMed  Google Scholar 

  51. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898–2908.

    Article  CAS  PubMed  Google Scholar 

  52. Bollineni JS, Reddi AS. Transforming growth factor-beta 1 enhances glomerular coolagen synthesis in diabetic rats. Diabetes 1993;42(11):1673–1677.

    Article  CAS  PubMed  Google Scholar 

  53. Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. J Renin Angiotensin Aldosterone Syst 2004;5(3):146–151.

    Article  CAS  PubMed  Google Scholar 

  54. Gilbert RE, Cox A, Wu LL, et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes. Diabetes 1998;47:414–422.

    Article  CAS  PubMed  Google Scholar 

  55. Benigni A, Zoja C, Corna D, et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816–1824.

    Article  CAS  PubMed  Google Scholar 

  56. Shankland SJ, Scholey JW, Ly H, Thai K. Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int 1994;46(2):430–442.

    Article  CAS  PubMed  Google Scholar 

  57. Hill C, Logan A, Smith C, Gronbaek H, Flyvbjerg A. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats. Diabetologia 2001;44(4):495–500.

    Article  CAS  PubMed  Google Scholar 

  58. Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11(1):25–38.

    CAS  PubMed  Google Scholar 

  59. Gonzalez-Albarran O, Gomez O, Ruiz E, Vieitez P, Garcia-Robles R. Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). Am J Hypertens 2003;16(11 Pt 1):979–985.

    Article  CAS  PubMed  Google Scholar 

  60. Shinomiya K, Fukunaga M, Kiyomoto H, et al. A role of oxidative stress-generated eicosanoid in the progression of arteriosclerosis in type 2 diabetes mellitus model rats. Hypertens Res 2002;25(1): 91–98.

    Article  CAS  PubMed  Google Scholar 

  61. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437.

    Article  CAS  PubMed  Google Scholar 

  62. Riser BL, Ladson-Wofford S, Sharba A, et al. TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int 1999;56(2):428–439.

    Article  CAS  PubMed  Google Scholar 

  63. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994;93:536–542.

    Article  CAS  PubMed  Google Scholar 

  64. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992;41:107–114.

    Article  CAS  PubMed  Google Scholar 

  65. Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system. Kidney Int 1998;53(3):631–638.

    Article  CAS  PubMed  Google Scholar 

  66. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91(20):9436–9440.

    Article  CAS  PubMed  Google Scholar 

  67. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 2004;165(6):2033–2043.

    CAS  PubMed  Google Scholar 

  68. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814–1818.

    Article  CAS  PubMed  Google Scholar 

  69. Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996;49(2):461–469.

    Article  CAS  PubMed  Google Scholar 

  70. Yoshioka K, Takemura T, Murakami K, et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68(2):154–163.

    CAS  PubMed  Google Scholar 

  71. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS. Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003;64(5):1715–1721.

    Article  CAS  PubMed  Google Scholar 

  72. De Muro P, Faedda R, Fresu P, et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res 2004;49(3):293–298.

    Article  PubMed  CAS  Google Scholar 

  73. Chan RW, Lai FM, Li EK, et al. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2004;50(9):2882–2890.

    Article  CAS  PubMed  Google Scholar 

  74. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care 1996;19(10):1113–1117.

    Article  CAS  PubMed  Google Scholar 

  75. Sato H, Iwano M, Akai Y, et al. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol 1998;18(6):490–494.

    Article  CAS  PubMed  Google Scholar 

  76. Fagerudd JA, Groop PH, Honkanen E, Teppo AM, Gronhagen-Riska C. Urinary excretion of TGF-beta 1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients. Kidney Int Suppl 1997;63: S195–S197.

    CAS  PubMed  Google Scholar 

  77. Cha DR, Kim IS, Kang YS, et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Diabet Med 2005;22(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  78. Komesli S, Vivien D, Dutartre P. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem 1998;254(3):505–513.

    Article  CAS  PubMed  Google Scholar 

  79. Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by transforming growth factor-beta receptor-IgG-Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465–475.

    Article  CAS  PubMed  Google Scholar 

  80. Akagi Y, Isaka Y, Arai M, et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulations in experimental glomerulonephritis. Kidney Int 1996; 50(1):148–155.

    Article  CAS  PubMed  Google Scholar 

  81. Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003;14(6):1535–1548.

    Article  CAS  PubMed  Google Scholar 

  82. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005;166(3):761–771.

    CAS  PubMed  Google Scholar 

  83. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112(10):1486–1494.

    CAS  PubMed  Google Scholar 

  84. Islam M, Burke JF, Jr., McGowan TA, et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001;59(2):498–506.

    Article  CAS  PubMed  Google Scholar 

  85. Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003;14(2):377–388.

    Article  CAS  PubMed  Google Scholar 

  86. Fukasawa H, Yamamoto T, Suzuki H, et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004;65(1):63–74.

    Article  CAS  PubMed  Google Scholar 

  87. Sharma K, Lin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522–530.

    Article  CAS  PubMed  Google Scholar 

  88. Ziyadeh FN, Hoffman BB, Cheol Han D, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansions by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97:8015–8020.

    Article  CAS  PubMed  Google Scholar 

  89. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003;300(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  90. Sharma R, Khanna A, Sharma M, Savin VJ. Transforming growth factor-betal increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney International 2000;58:131–136.

    Article  CAS  PubMed  Google Scholar 

  91. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J Physiol 2002;283:R757–R767.

    CAS  Google Scholar 

  92. Kelly FJ, Anderson S, Thompson MM, et al. Acute and chronic renal effects of recombinant human TGF-beta2 in the rat. J Am Soc Nephrol 1999;10:1264–1273.

    CAS  PubMed  Google Scholar 

  93. Kato S, Luyckx VA, Ots M, et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999;56:1037–1048.

    Article  CAS  PubMed  Google Scholar 

  94. Benigni A, Zoja C, Campana M, et al. Beneficial effect of TGF beta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 2006;104(4):e158–e168.

    Article  CAS  PubMed  Google Scholar 

  95. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351(19):1941–1951.

    Article  CAS  PubMed  Google Scholar 

  96. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1(4):328–335.

    Article  CAS  PubMed  Google Scholar 

  97. Praga M, Andrade CF, Luno J, et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18(9):1806–1813.

    Article  CAS  PubMed  Google Scholar 

  98. Song JH, Lee SW Suh JH, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003;60(5):318–326.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Medicine, Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    Elena Gagliardini PhD & Ariela Benigni PhD

Authors
  1. Elena Gagliardini PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ariela Benigni PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Training Branch, Office of Centers, Training and Resources, National Cancer Institute, Bethesda, MD

    Sonia B. Jakowlew PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Gagliardini, E., Benigni, A. (2008). Role of Transforming Growth Factor-β in the Kidney — Physiology and Pathology. In: Jakowlew, S.B. (eds) Transforming Growth Factor-β in Cancer Therapy, Volume II. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-293-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-293-9_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-715-0

  • Online ISBN: 978-1-59745-293-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation